Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in a Neutropenic Murine Thigh Infection Model-Reference-Cited by-同舟云学术

Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in a Neutropenic Murine Thigh Infection Model

Published:2020-02-21 Issue:3 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Asempa Tomefa E.¹,Abdelraouf Kamilia¹,Carabeo Teresa²,Schuch Raymond²^ORCID,Nicolau David P.¹³

Affiliation:

1. Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA

2. Contrafect Corporation, Yonkers, New York, USA

3. Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA

Abstract

We evaluated the efficacy of escalating doses of exebacase administered with subtherapeutic daptomycin exposures against 8 Staphylococcus aureus isolates in a neutropenic murine thigh infection model. Daptomycin alone resulted in mean growth of 0.39 ± 1.19 log 10 CFU/thigh.

Funder

ContraFect

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02176-19

Reference16 articles.

1. The Burden of Staphylococcus aureus Infections on Hospitals in the United States

2. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

3. Cell wall hydrolases and antibiotics: exploiting synergy to create efficacious new antimicrobial treatments